Clinical trials evaluating TZP in inflammatory allergic diseases have shown improvements in asthma exacerbation rates, inflammatory biomarkers, and lung function.12 Given TSLP’s extensive role within the immunologic network and TZP’s ability to counteract this activity, it is essential to identify patients who are most likely to benefit from TZP. The gene discussed is TSLP; the disease is asthma.